Long-term data with idebenone on respiratory function outcomes in patients with Duchenne muscular dystrophy
Decline in respiratory function in patients with DMD starts during early teenage years and leads to early morbidity and mortality. Published evidence of efficacy for idebenone on respiratory function outcomes is currently limited to 12 months of follow-up time. Here we report data collected as retro...
主要な著者: | Servais, L, Straathof, CSM, Schara, U, Klein, A, Leinonen, M, Hasham, S, Meier, T, De Waele, L, Gordish-Dressman, H, McDonald, CM, Mayer, OH, Voit, T, Mercuri, E, Buyse, GM |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
Elsevier
2019
|
類似資料
-
Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy
著者:: Theodora Markati, 等
出版事項: (2021-11-01) -
Evidence for ACTN3 as a genetic modifier of Duchenne muscular dystrophy
著者:: Marshall W. Hogarth, 等
出版事項: (2017-01-01) -
Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy
著者:: Fatima Amor, 等
出版事項: (2021-06-01) -
Genetic modifiers of respiratory function in Duchenne muscular dystrophy
著者:: Luca Bello, 等
出版事項: (2020-05-01) -
Duchenne Muscular Dystrophy
著者:: J Gordon Millichap
出版事項: (1989-05-01)